CureVac

Founder / s: Ingmar Hoerr
Key people : Ingmar Hoerr (Founder & CEO), Franz-Werner Haas (Chief Corporate Officer), Oliver Schlüter (Chief Financial Officer), Florian von der Mülbe (Chief Operating Officer), Mariola Fotin-Mleczek ( Chief Scientific Officer) and Ulrike Gnad-Vogt (Chief Medical Officer)
Number of employees : 251 – 500

CureVac GmbH is a biopharmaceutical company produced in the prophylactic and therapeutic application of messenger RNA (mRNA). CureVac’s lead program is dedicated to the development of active immunotherapies (based on its RNActive technology) for the treatment of prostate cancer and non- Accident, in Preclinical studies, CureVac is developing prophylactic vaccines and adjuvants to address infectious diseases.

History

In October 2013 Curevac launched a collaboration with Janssen Pharmaceuticals Inc., a Johnson & Johnson company, for the development of novel flu vaccines.

In November 2013, CureVac announced the fourth in a series of partners with the Cancer Research Institute and Ludwig Cancer Research to enable clinical testing of novel cancer immunotherapy treatment options.

On March 10, 2014, CureVac won a € 2 million prize grant by the European Commission to stimulate new technology technologies hope that the developing world, because the company’s research could lead to a new generation of vaccines that do not need refrigeration.

In July 2014, CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine.

In September 2014 the company licensed the global rights for its Phase I candidate – CV9202 – to Boehringer Ingelheim. Boehringer plans to conduct trials using the mRNA antibody in combination with afatinib in advanced and / or metastatic epidermal growth factor receptor (EGFR) mutated non- Small cell lung cancer (NSCLC) as well as inoperable stage III NSCLC. This can culminate in netting the company about $ 600 million.

In March 2015, CureVac’s investor, the Bill & Melinda Gates Foundation, agreed to provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary mRNA platform

In August 2015, CureVac announces its initiation of its third target product development program in collaboration with the Bill & Melinda Gates Foundation. The program will leverage CureVac’s RNActive® technology platform in the development of a prophylactic vaccine to protect against respiratory syncytial virus (RSV) , Adding to the development programs had initiated by CureVac and the Gates Foundation targeting mRNA vaccines for HIV and Rotavirus.

In 2009, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the development of AIDS vaccines, using immunogens developed by IAVI and partners, delivered via CureVac’s mRNA technology.

In September 2015, CureVac announced it would be opening a United States hub in Cambridge, Massachusetts.

Quot; a & lt; / RTI & gt; published a change of its corporate legal form to a joint stock company, Aktiengesellschaft (& lt; RTI ID = 0.0 & gt; AG). This new molten round was led by Baillie Gifford, Adding to the nearest $ 220 million CureVac has raised since its founding in 2000. The new investors, Baillie Gifford, Chartwave Limited, Coppel Family, Northview and Sigma Group, join existing investors dievini Hopp BioTech holding GmbH & Co. KG of Dietmar Hopp and The Bill & Melinda Gates Foundation.